Antilipidemic Drugs

Correct Answer

C — Rosuvastatin

Rationale

Rosuvastatin is classified as a hydrophilic statin. Hydrophilic statins rely on active hepatic uptake transporters rather than passive diffusion across cell membranes, giving them greater selectivity for the liver. Atorvastatin, simvastatin, and lovastatin are all classified as lipophilic statins, which passively diffuse across cell membranes and distribute more broadly to tissues including skeletal muscle.

Correct Answer

A — Simvastatin

Rationale

Simvastatin is classified as an inactive prodrug. It is administered in a closed lactone form that requires hydrolysis to an open hydroxy acid form before it can inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase. This prodrug status, combined with its short-lived active metabolites, contributes to simvastatin having the highest drug interaction risk among the commonly used statins. Atorvastatin, rosuvastatin, and pravastatin are all administered as active drugs that do not require prior metabolic activation.

Correct Answer

D — Pravastatin

Rationale

Pravastatin is classified as a hydrophilic statin that uses non-cytochrome P450 metabolic pathways — primarily sulfation and hydroxylation — for its elimination. This metabolic profile gives pravastatin a low cytochrome P450 drug interaction risk and makes it a preferred statin in patients where cytochrome P450-mediated interactions are a concern, such as solid organ transplant recipients on cyclosporine. Atorvastatin, simvastatin, and lovastatin are all metabolized primarily by cytochrome P450 3A4 and carry a substantially higher drug interaction risk.

Correct Answer

B — Atorvastatin and rosuvastatin

Rationale

Atorvastatin and rosuvastatin are the two statins classified as high-intensity agents at their maximum doses — atorvastatin 40 to 80 milligrams daily and rosuvastatin 20 to 40 milligrams daily — producing expected low-density lipoprotein cholesterol reductions of 50 percent or more from untreated baseline. Simvastatin and lovastatin are classified as moderate-intensity statins at their standard doses; their maximum doses carry greater toxicity risk without providing high-intensity efficacy. Pravastatin, fluvastatin, and pitavastatin are also classified as moderate-intensity statins. Low-intensity agents such as simvastatin 10 milligrams are reserved for patients who cannot tolerate higher intensities.

Correct Answer

A — Fluvastatin

Rationale

Fluvastatin is classified as a cytochrome P450 2C9 substrate, which distinguishes it from most other statins. Cytochrome P450 2C9 inhibitors — such as fluconazole and amiodarone — increase fluvastatin exposure and may raise the risk of muscle toxicity. Atorvastatin, simvastatin, and lovastatin are all classified as cytochrome P450 3A4 substrates, making them susceptible to a different and broader set of drug interactions involving cytochrome P450 3A4 inhibitors such as azole antifungals and macrolide antibiotics.

Correct Answer

C — Gemfibrozil

Rationale

Gemfibrozil is classified as an inhibitor of hepatic organic anion-transporting polypeptide 1B1 uptake transporters. These transporters are responsible for moving statins from the portal circulation into hepatocytes for metabolism and biliary excretion. Gemfibrozil also inhibits the glucuronidation pathway that clears statin lactone forms. Together, these interactions raise statin plasma concentrations substantially and create a clinically important rhabdomyolysis risk with any statin. Fenofibrate does not share this transporter-inhibition profile and is the preferred fibrate when combination therapy with a statin is required.

Correct Answer

B — Statin-induced sterol regulatory element-binding protein 2 activation simultaneously upregulates proprotein convertase subtilisin/kexin type 9, which destroys low-density lipoprotein receptors and partially offsets the benefit of greater receptor upregulation at higher doses

Rationale

Statin-induced cholesterol depletion activates sterol regulatory element-binding protein 2, which upregulates both the low-density lipoprotein receptor gene and the proprotein convertase subtilisin/kexin type 9 gene — because both contain sterol regulatory element-binding protein 2 response elements. At higher doses, more proprotein convertase subtilisin/kexin type 9 is produced, directing more low-density lipoprotein receptors toward lysosomal degradation. This built-in counterregulatory brake causes the statin dose-response curve to follow a log-linear relationship that plateaus, such that each doubling of the dose from any starting point adds only approximately 6 percent additional low-density lipoprotein cholesterol reduction. This principle — the rule of 6s — explains why adding a second agent such as ezetimibe or a proprotein convertase subtilisin/kexin type 9 inhibitor is more effective than dose doubling when the target is not met.

Correct Answer

D — Inhibition of non-sterol isoprenoid intermediates in the mevalonate pathway, which are required for post-translational modification of small signaling proteins that regulate inflammation and endothelial function

Rationale

The mevalonate pathway produces not only cholesterol but also non-sterol isoprenoid intermediates — including farnesyl pyrophosphate and geranylgeranyl pyrophosphate — that are required for the post-translational modification of small signaling proteins such as Rho, Rac, and Ras GTPases. These proteins regulate inflammatory signaling, endothelial nitric oxide synthase activity, and macrophage behavior in atherosclerotic plaques. Statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase reduces the supply of these isoprenoid intermediates, producing anti-inflammatory, endothelial-protective, plaque-stabilizing, and antithrombotic effects that begin within days of statin initiation — well before meaningful low-density lipoprotein cholesterol reduction occurs. Option C describes the primary lipid-lowering mechanism, not the pleiotropic mechanism.

Correct Answer

A — Lipophilic statins passively diffuse across cell membranes and distribute broadly into skeletal muscle, resulting in higher intramuscular drug concentrations than hydrophilic statins achieve

Rationale

Lipophilic statins — including atorvastatin, simvastatin, lovastatin, fluvastatin, and pitavastatin — passively diffuse across cell membranes and distribute into a wide range of tissues, including skeletal muscle. Hydrophilic statins — rosuvastatin and pravastatin — rely on active hepatic uptake transporters and demonstrate much greater selectivity for the liver, with limited penetration into non-hepatic tissues such as skeletal muscle. The greater skeletal muscle penetration of lipophilic statins is thought to account for their somewhat higher risk of statin-associated muscle symptoms. This is one reason rosuvastatin is sometimes preferred in patients with a history of statin myalgia, despite being among the most potent statins available.

Correct Answer

C — Itraconazole inhibits cytochrome P450 3A4, the enzyme responsible for simvastatin metabolism, reducing simvastatin clearance and raising its plasma concentrations several-fold

Rationale

Simvastatin is metabolized primarily by cytochrome P450 3A4. Itraconazole is a potent cytochrome P450 3A4 inhibitor. Co-administration blocks simvastatin metabolism, dramatically reducing its clearance and raising plasma concentrations several-fold. The resulting increase in statin exposure — particularly in skeletal muscle given simvastatin's lipophilic nature — substantially raises the risk of myopathy and rhabdomyolysis. This interaction applies to all cytochrome P450 3A4-metabolized statins, including atorvastatin and lovastatin. When a patient requires long-term treatment with a strong cytochrome P450 3A4 inhibitor, switching to rosuvastatin or pravastatin — which have minimal cytochrome P450 metabolism — avoids this interaction entirely. Itraconazole does not displace statins from protein binding, does not inhibit the reductase enzyme directly, and does not impair renal excretion of metabolites.

Correct Answer

B — Rosuvastatin, because it undergoes minimal cytochrome P450 metabolism and is therefore not meaningfully affected by cytochrome P450 3A4 inhibition

Rationale

Rosuvastatin relies primarily on hepatic organic anion-transporting polypeptide 1B1 uptake transporters for its delivery to the liver, with minimal dependence on cytochrome P450 enzymes for metabolism or clearance. Cytochrome P450 3A4 inhibitors such as human immunodeficiency virus protease inhibitors therefore do not meaningfully raise rosuvastatin plasma concentrations, making it the preferred choice in this setting. Atorvastatin and lovastatin are cytochrome P450 3A4 substrates and carry substantially elevated myopathy risk with potent inhibitors. Simvastatin dose reduction does not reliably prevent rhabdomyolysis with strong inhibitors and is generally contraindicated with this combination. Lovastatin is also a cytochrome P450 3A4-metabolized prodrug and shares simvastatin's high interaction risk — its prodrug nature does not protect against cytochrome P450 3A4 inhibition.

Correct Answer

A — Gemfibrozil inhibits the hepatic uptake transporters that clear statins from the blood and blocks the glucuronidation pathway that eliminates statin lactone forms, raising statin plasma concentrations and rhabdomyolysis risk; fenofibrate does not share these inhibitory effects

Rationale

Gemfibrozil potently inhibits two separate pathways that normally clear statins from the circulation: organic anion-transporting polypeptide 1B1 hepatic uptake transporters, which move statins from portal blood into hepatocytes, and the glucuronidation pathway that eliminates the lactone forms of statins from the body. Blocking both pathways raises statin plasma concentrations substantially — enough to produce myopathy or rhabdomyolysis with any statin. Fenofibrate does not inhibit these transporters or glucuronidation and therefore does not meaningfully raise statin levels. When a fibrate is needed alongside statin therapy, fenofibrate is always preferred over gemfibrozil. The interaction is not explained by shared receptor activation, renal metabolite accumulation, or relative potency differences between the two fibrates.

Correct Answer

D — Pleiotropic effects — including plaque stabilization, improved endothelial function, anti-inflammatory activity, and reduced platelet aggregability — begin within days of statin initiation through inhibition of isoprenoid intermediates, independent of low-density lipoprotein cholesterol reduction

Rationale

The pleiotropic effects of statins — mediated by depletion of non-sterol isoprenoid intermediates in the mevalonate pathway — begin within days of initiation. High-sensitivity C-reactive protein falls rapidly, endothelial nitric oxide synthase activity increases, atherosclerotic plaques become more stable through increased fibrous cap thickness and reduced macrophage infiltration, and platelet aggregability is reduced. These changes collectively reduce the risk of acute thrombotic events from vulnerable plaque rupture within weeks of starting therapy, long before the gradual cholesterol-lowering effect could produce any structural benefit. This is why high-intensity statin therapy is initiated within 24 hours of an acute coronary syndrome presentation regardless of the baseline low-density lipoprotein cholesterol level. Statins do not rapidly lower low-density lipoprotein cholesterol within the first week, do not upregulate macrophage low-density lipoprotein receptors, and do not meaningfully raise high-density lipoprotein cholesterol.

Correct Answer

C — The benefit of early statin therapy in acute coronary syndrome derives from pleiotropic effects — plaque stabilization, improved endothelial function, and anti-inflammatory activity — that begin within days and are independent of the baseline low-density lipoprotein cholesterol level

Rationale

High-intensity statin therapy is initiated within 24 hours of acute coronary syndrome because its early benefit comes from pleiotropic effects, not from low-density lipoprotein cholesterol reduction. Plaque stabilization through increased fibrous cap thickness and reduced macrophage content, improved endothelial nitric oxide synthesis, reduced systemic inflammation, and decreased platelet aggregability all begin within days — effects mediated by depletion of isoprenoid intermediates in the mevalonate pathway. Because these benefits occur regardless of the starting low-density lipoprotein cholesterol level, waiting for a lipid panel before initiating therapy offers no clinical advantage and risks losing days of pleiotropic benefit at a time when vulnerable plaques are most likely to rupture. Acute coronary syndrome does not define a minimum low-density lipoprotein cholesterol threshold, and statins do not meaningfully lower low-density lipoprotein cholesterol within the first 24 hours.

Correct Answer

B — Clarithromycin inhibits cytochrome P450 3A4, the enzyme responsible for simvastatin metabolism, raising simvastatin plasma concentrations and increasing skeletal muscle drug exposure to toxic levels

Rationale

Clarithromycin is a macrolide antibiotic and a potent inhibitor of cytochrome P450 3A4. Simvastatin is a cytochrome P450 3A4-metabolized inactive prodrug with short-lived active metabolites and a narrow buffer against concentration spikes. When cytochrome P450 3A4 is inhibited, simvastatin clearance is dramatically reduced, plasma concentrations rise several-fold, and — given simvastatin's lipophilic nature — skeletal muscle exposure increases proportionally, producing myopathy that can progress to rhabdomyolysis. When a short course of a cytochrome P450 3A4 inhibitor antibiotic is required, the recommended approach is to hold the statin for the duration of treatment. Switching to rosuvastatin or pravastatin for patients who require long-term cytochrome P450 3A4 inhibitors avoids this interaction entirely. Clarithromycin does not directly damage mitochondria, does not displace simvastatin from protein binding, and does not inhibit organic anion-transporting polypeptide 1B1 transporters — that mechanism belongs to gemfibrozil.

Correct Answer

D — Doubling the statin dose from any point adds only approximately 6 percent additional low-density lipoprotein cholesterol reduction due to the counterregulatory proprotein convertase subtilisin/kexin type 9 co-induction, while adding ezetimibe produces a meaningful additional reduction via a complementary mechanism

Rationale

The statin dose-response curve is log-linear with a plateau: each doubling of the dose from any starting point adds only approximately 6 percent additional low-density lipoprotein cholesterol reduction, because the sterol regulatory element-binding protein 2 activation that upregulates low-density lipoprotein receptors simultaneously upregulates proprotein convertase subtilisin/kexin type 9, which destroys those receptors. Doubling rosuvastatin from 20 to 40 milligrams would therefore yield only a modest additional reduction — likely insufficient to reach target — while meaningfully increasing the risk of myalgia in a patient already prone to it. Ezetimibe, by contrast, reduces hepatic cholesterol delivery through a completely different route — Niemann-Pick C1-Like 1 transporter inhibition — and produces 18 to 25 percent additional low-density lipoprotein cholesterol reduction when added to a statin. This pharmacological principle — the rule of 6s — is why guidelines recommend adding a second agent rather than escalating the statin when the target is not met on maximally tolerated therapy. The pharmacological basis for the add-on approach is well established: ezetimibe targets a different input to the hepatic cholesterol pool and produces meaningful additional low-density lipoprotein cholesterol lowering that dose escalation cannot match given the log-linear ceiling.

Correct Answer

A — Initiate high-intensity statin therapy within 24 hours regardless of the baseline low-density lipoprotein cholesterol level, because early benefit derives from pleiotropic effects that begin within days

Rationale

High-intensity statin therapy — atorvastatin 40 to 80 milligrams or rosuvastatin 20 to 40 milligrams — should be initiated within 24 hours of an acute coronary syndrome presentation without waiting for lipid results. The pharmacological rationale is that the early benefit of statins in this setting is driven by pleiotropic effects mediated through inhibition of mevalonate pathway isoprenoid intermediates: plaque stabilization, improved endothelial nitric oxide production, reduced systemic inflammation, and decreased platelet aggregability begin within days of initiation. These benefits occur independently of the baseline low-density lipoprotein cholesterol level, so the lipid result does not change the treatment decision. Starting at moderate intensity or waiting for discharge sacrifices days of pleiotropic benefit during the period of greatest plaque vulnerability. The acute inflammatory state of myocardial infarction does not increase statin myopathy risk and is not a reason to defer therapy.

Correct Answer

C — Pravastatin, because it uses non-cytochrome P450 metabolic pathways and has the best-established safety record in solid organ transplant recipients on cyclosporine

Rationale

Pravastatin is the preferred statin in solid organ transplant patients on cyclosporine. It is a hydrophilic statin that uses non-cytochrome P450 metabolic pathways — primarily sulfation and hydroxylation — and is therefore not meaningfully affected by cyclosporine's inhibition of cytochrome P450 3A4 and organic anion-transporting polypeptide 1B1 transporters. Pravastatin has the longest safety record in this population and the lowest drug interaction liability. Fluvastatin is also an acceptable alternative. Atorvastatin can be used at reduced doses but carries higher interaction risk than pravastatin. Rosuvastatin is partially affected by organic anion-transporting polypeptide 1B1 transporter inhibition by cyclosporine and should be used cautiously at reduced doses — it is not completely unaffected as option B implies. Simvastatin and lovastatin are avoided in transplant patients on cyclosporine because of high rhabdomyolysis risk; simvastatin's prodrug nature does not protect against this interaction.